Eloxx Pharmaceuticals focuses on the discovery, development, and commercialization of compounds for the treatment of rare genetic diseases including cystic fibrosis, Duchenne muscular dystrophy, Usher syndrome, ataxia-telangiectasia, beta thalassemia, and Tay-Sachs Hurler syndrome.The companys approach allows it to move rapidly from a target drug-discovery program to clinical drug candidates.

Eloxx Pharmaceuticals is building a pipeline of molecules designed for an array of genetic diseases caused by nonsense mutations.In June 2017, Eloxx Pharmaceuticals reverse-merged with Sevion Therapeutics Inc.

This acquisition transitioned Eloxx from a private to a publicly traded company.